Gemcitabine was the first line therapy for neoadjuvant chemotherapy for locally advanced pancreatic cancer during that time, however, its ORR was unsatisfactory compared with FOLFIRINOX or gemcitabine+albumin-bound paclitaxel regimens. This evidence concerns the gene ALB and pancreatic neoplasm.